Clinical trials: Breast Neoplasms, Triple-Negative
Triple Negative Breast Cancer
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)
This study is a randomized, positive parallel controlled, multicentre phase III clinical trial to evaluate the efficacy and safety of TQB2450 combined with anlotinib versus paclitaxel for injection (albumin bound) in subjects…
- Trial name
- NCT04405505
- Testing
- TQB2450, Anlotinib, Paclitaxel for Injection (albumin bound)
- Where
- 30 sites in China
- Volunteers
- 332 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Triple Negative Breast Cancer, Triple Negative Breast Neoplasms
Image-based AI Predictive Biomarkers for Precision Neoadjuvant Triple-negative Breast Cancer Treatment
Pear Bio has developed an organ-on-a-chip device together with a computer vision pipeline through which the response of an individual patient's tumor to different chemotherapy regimens can be tested simultaneously ex vivo.
- Trial name
- PEAR-TNBC (NCT05435352)
- Testing
- Core needle biopsy
- Where
- 3 sites in United Kingdom
- Volunteers
- 34 people
- Sponsor
- Ourotech, Inc.
Ovarian Carcinoma, Fallopian Tube Carcinoma
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
This is a first-in-human, open-label, multi-center, Phase 1, dose-escalation study with expansion cohorts to evaluate NM32-2668 for safety and immunogenicity, to determine the maximal tolerated dose and recommended Phase 2 dose…
- Conditions
- Ovarian Carcinoma, Fallopian Tube Carcinoma, Peritoneal Carcinoma, Endometrial Cancer
- Trial name
- NCT06299163
- Testing
- NM32-2668
- Where
- 11 sites in United States
- Volunteers
- 11 people
- Sponsor
- Numab Therapeutics AG
Triple Negative Breast Cancer
Neoadjuvant Nivolumab and Chemotherapy in Patients With Localized Triple-negative Breast Cancer
Prior to Amendment #7: The hypothesis of this study is that the combination of cabiralizumab and nivolumab with neoadjuvant chemotherapy will decrease tumor associated macrophages (TAMs) and increase tumor infiltrating…
- Trial name
- NCT04331067
- Testing
- Paclitaxel, Carboplatin, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Washington University School of Medicine
Triple Negative Breast Cancer(TNBC)
PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic TNBC
This multicenter, randomized, double-blind study will evaluate the safety and efficacy of PM8002 in combination with Nab-Paclitaxel compared with placebo combined with Nab-Paclitaxel as first-line treatment in inoperable locally…
- Trial name
- NCT06419621
- Testing
- PM8002, Nab-Paclitaxel
- Where
- 70 sites in China
- Volunteers
- 392 people
- Sponsor
- Biotheus Inc.
Stage III Breast Cancer, Stage IIIA Breast Cancer
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
This phase II trial studies how well the combination of avelumab with liposomal doxorubicin with or without binimetinib, or the combination of avelumab with sacituzumab govitecan works in treating patients with triple negative…
- Conditions
- Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
- Trial name
- InCITe (NCT03971409)
- Testing
- Anti-OX40 Antibody PF-04518600, Avelumab, Binimetinib
- Where
- 12 sites in United States
- Volunteers
- 145 people
- Sponsor
- Laura Huppert, MD, BA
Advanced Triple-negative Breast Cancer
Phase II Clinical Trial of PD-L1 in Combination With Vinorelbine + Cyclophosphamide + Capecitabine (VEX) Metronomic Chemotherapy With or Without Radiotherapy for Advanced Triple-negative Breast Cancer.
Phase II clinical trial of PD-L1 in combination with vinorelbine + cyclophosphamide + capecitabine (VEX) metronomic chemotherapy with or without radiotherapy for advanced triple-negative breast cancer.
- Trial name
- NCT06771609
- Testing
- Adebrelimab + VEX metronomic chemotherapy + radiotherapy, Adebrelimab + VEX metronomic chemotherapy
- Where
- 2 sites in China
- Volunteers
- 150 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Triple Negative Breast Cancer
Microbiome Immunotherapy Neoadjuvant Assessment
Predictive biomarkers of response to combination chemotherapy and immune-checkpoint inhibitors are urgently needed to help tailor treatment recommendations for patients with early-stage TNBC.
- Trial name
- MINA (NCT06709651)
- Where
- Ireland
- Volunteers
- 30 people
- Sponsor
- University College Cork
Triple Negative Breast Cancer
Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)
The purpose of this study is to determine if GTx-024 is effective and safe in the treatment of patients with advanced, androgen receptor positive triple negative breast cancer (AR+ TNBC).
- Trial name
- NCT02368691
- Testing
- GTx-024
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- GTx
Triple-Negative Breast Cancer (TNBC)
Metabolic Flexibility in Patients With Early Triple-negative Breast Cancer
Cancer is considered a major global public health problem. It was estimated that in 2022 approximately 19.9 million new cancer cases were diagnosed worldwide, and this number is expected to increase over the next two decades to…
- Trial name
- NCT07484776
- Testing
- Cardiovascular training at maximal fat oxidation (FATmax), Cardiovascular training at maximal aerobic power (MAP), Resistance training
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Universidad Europea de Madrid
Adult Solid Neoplasm, Estrogen Receptor Negative
Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors
This phase I clinical trial studies the side effects and the best dose of veliparib when given together with carboplatin and paclitaxel in treating patients with locally advanced or metastatic solid tumors.
- Conditions
- Adult Solid Neoplasm, Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative
- Trial name
- NCT01281150
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Paclitaxel
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
Early triple negative breast cancer patients who do not achieve pathologic complete response after neoadjuvant chemotherapy with or without immunotherapy have bad prognosis.
- Trial name
- NCT06992336
- Testing
- Apatinib, Camrelizumab, Capecitabine
- Where
- China
- Volunteers
- 430 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Metastatic Breast Cancer
Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer
Taxanes (such as paclitaxel) are highly active to treat breast cancer. Abraxane® (nanoparticle albumin-bound paclitaxel) compared to standard paclitaxel improves efficacy and tolerability.
- Trial name
- NCT01207102
- Testing
- Abraxane, Carboplatin
- Where
- 2 sites in United States, China
- Volunteers
- 10 people
- Sponsor
- Duke University
Breast Cancer Invasive
Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy
The primary aim is to evaluate the efficacy of neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy in patients with triple-negative breast cancer, with the endpoint being the pCR rate-defined as the…
- Trial name
- NCT06691594
- Testing
- neoadjuvant SBRT combined with PD-1 monoclonal antibody and chemotherapy
- Volunteers
- 20 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Advanced Solid Tumors Cancer
A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors
The primary purpose of this Phase 1, open-label study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-368 as a monotherapy and in combination with ABBV-181 in participants with locally advanced or…
- Trial name
- NCT03071757
- Testing
- ABBV-368, ABBV-181
- Where
- 27 sites in United States, France and 4 more
- Volunteers
- 139 people
- Sponsor
- AbbVie
Breast Cancer, Obesity
Effect of Diet and Exercise in Breast Cancer Survivors
This study seeks to see if a 12-week diet and exercise program improves exercise ability, energy level, and quality of life.
- Trial name
- F4F tri neg (NCT01498536)
- Testing
- aerobic exercise
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- West Virginia University
Breast Cancer
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with…
- Trial name
- NCT06103864
- Testing
- Dato-DXd, Durvalumab, Paclitaxel
- Where
- 318 sites in United States, Argentina and 22 more
- Volunteers
- 625 people
- Sponsor
- AstraZeneca
Triple-negative Breast Cancer
FUSCC Refractory TNBC Umbrella (FUTURE)
This is a Phase Ib/II, open-label, multi-center umbrella study evaluating the efficacy and safety of multiple targeted treatment in patients with refractory metastatic TNBC.The specific grouping of patients' depends on FUSCC 500+…
- Trial name
- FUTURE (NCT03805399)
- Testing
- Pyrotinib with Capecitabine, AR inhibitor combined with everolimus(B1) or CDK4/6 inhibitor(B2),or EZH2 inhibitor (B4), anti PD-1 with nab-paclitaxel
- Where
- China
- Volunteers
- 140 people
- Sponsor
- Fudan University
Breast Cancer
Trial of RAD001 in Triple Negative Metastatic Breast Cancer
The hypothesis of this clinical research study is to discover if the study drug RAD001 can shrink or slow the growth of Estrogen Receptor/Progesterone Receptor (ER/PR) negative or Human Epidermal growth factor Receptor 2 (Her2…
- Trial name
- NCT00827567
- Testing
- RAD 001
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Milton S. Hershey Medical Center